Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309945 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 889
- Enrollment target
NCT01309945 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 889 participants.
The verdict
NCT01309945, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 889 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
Interventions
- DRUG Duloxetine
- DRUG BMS-820836
- DRUG Placebo matching with BMS-820836
- DRUG Placebo matching with Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 889 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01309945
The ClinicalTrials.gov registry entry for NCT01309945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 889 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Duloxetine is the first listed.
NCT01309945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01309945 about?
NCT01309945 is a clinical study titled "Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression". The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
What is the current status of trial NCT01309945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 889 participants. The study started on 2011-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01309945?
The interventions under investigation include: Duloxetine (DRUG), BMS-820836 (DRUG), Placebo matching with BMS-820836 (DRUG), Placebo matching with Duloxetine (DRUG).
Who is sponsoring clinical trial NCT01309945?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.